White Paper | Optimizing Backfilling Strategies for Phase I Oncology Studies

In early development, if safety is not an issue, the optimal dose is the dose that is the most effective. Response rate is generally the preferred criteria. However, how can we determine the best dose with small sample sizes? The main dilemma is to deliver far too large dose as long as safety do not stop the escalation.

"*" indicates required fields

Please enter your details to get access to the resource

By submitting this form, you consent to your personal data submitted in the form being processed in alignment with our Online Privacy and Cookies policy. Your personal data will be processed to facilitate your request and may be used for sending you additional marketing and business development-related information about Ergomed, its affiliates, and our services. You can withdraw your consent anytime by messaging marketing@wordpress-546467-1930493.cloudwaysapps.com, and we will promptly remove your data from our records. For more information about how we will process your personal data and your rights, please see our Online Privacy and Cookies policy.
This field is for validation purposes and should be left unchanged.